Pfizer get USFDA nod for XELJANZ (tofacitinib) to treat active polyarticular course juvenile idiopathic arthritis
Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight
Pfizer announced that the United States (US) Food and Drug Administration (FDA) approved XELJANZÂ (tofacitinib) for